Clinical trial

Efficacy and Safety of Roflumilast in Japanese Patients Older Than 40 Years With…

NCT00242294 · AstraZeneca, Industry · Completed

Key facts

NCT number NCT00242294
Title Efficacy and Safety of Roflumilast in Japanese Patients Older Than 40 Years With Chronic Obstructive Pulmonary Disease (APTA-2217-06)
Official title A Confirmatory Study of APTA-2217 in Patients With Chronic Obstructive Pulmonary Disease (A Placebo-controlled Double-blind Comparative Study)
Lead sponsor AstraZeneca, Industry
Collaborators Tanabe Pharma Corporation Industry
Status Completed
Phase Phase 2/Phase 3
Study type Interventional
Conditions Chronic Obstructive Pulmonary Disease (COPD)
Intervention type Drug
Interventions Roflumilast
Enrollment 570
Start date Nov 1, 2004
Primary completion Sep 1, 2006
Completion Mar 1, 2007
First posted Oct 20, 2005
Last update posted Oct 26, 2016
Countries Japan

At a glance

  • 1–9 Study sites
  • No Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies